Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma-Reference-Cited by-同舟云学术

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Published:2018-11 Issue:11 Volume:13 Page:e232-e234
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Giroux-Leprieur Etienne,Dumenil Coraline,Chinet Thierry

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Response to crizotinib/erlotinib combination in a patient with a primary EGFR-mutant adenocarcinoma and a primary c-met–amplified g;Dietrich;J Thorac Oncol,2015

2. Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplification;Gainor;J Thorac Oncol,2016

3. Tolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer;York;J Thorac Oncol,2017

4. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C;Li;Ann Oncol,2017

5. Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors;Baldacci;Oncotarget,2017

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rebiopsie tumorale : quand ? pour qui ? pourquoi ? comment ?;Revue des Maladies Respiratoires Actualités;2023-10

2. Clinical trial designs for evaluating and exploiting cancer evolution;Cancer Treatment Reviews;2023-07

3. Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key;International Journal of Molecular Sciences;2023-03-14

4. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions;Frontiers of Medicine;2023-02

5. The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC;Biomedicine & Pharmacotherapy;2022-12